Erythropoietin Expression Promoter

摘要

The present invention provides an erythropoietin expression-enhancing agent that can cancel the suppression of erythropoietin production or promote erythropoietin production, and a therapeutic or preventive drug for anemia, a liver function-improving agent, an ischemic injury-improving agent, a renal protective agent, and an insulin secretagogue comprising the erythropoietin expression-enhancing agent. The erythropoietin expression-enhancing agent of the present invention comprises one or more compounds selected from the group consisting of compounds represented by the following general formulas (I), (II), and (III) and pharmaceutically acceptable salts thereof when R3 is OH.;

主权项

1. A method for treating a disease caused by reduced erythropoietin expression or reduced erythropoietin reactivity, comprising administering an erythropoietin expression-enhancing agent to a patient in need of enhancement in erythropoietin expression, wherein the erythropoietin expression-enhancing agent comprises one or more compounds selected from the group consisting of a compound represented by the following formula (I): [wherein R1 represents a benzoylmethyl group whose benzene ring is unsubstituted or substituted by an alkyl group having 1 to 7 carbon atoms, an alkoxyl group having 1 to 7 carbon atoms, fluorine, and/or chlorine, an unsubstituted or fluorine-substituted linear or branched alkyl group having 4 to 6 carbon atoms, or phenyl group- or cyclopentyl group-substituted methylene or ethylene, wherein the phenyl group is optionally further substituted by one or more phenyl groups, R2 substitutes positions 4, 5, 6, and/or 7 of indole and is selected from the group consisting of hydrogen, an alkyl group having 1 to 4 carbon atoms, an alkoxyl group having 1 to 7 carbon atoms, fluorine, and chlorine, R3 represents any one group selected from OH, OR4, NHR4, and NR4R5, and R4 and R5 are the same or different and each represents a substituted or unsubstituted alkyl group having 1 to 4 carbon atoms], the following formula (II): [wherein R6 represents hydrogen or a methyl group, X represents an alkylene group having 4 to 6 carbon atoms or an ether group having 4 carbon atoms, R3 represents any one group selected from OH, OR4, NHR4, and NR4R5, and R4 and R5 are the same or different and each represents a substituted or unsubstituted alkyl group having 1 to 4 carbon atoms], and the following formula (III): [wherein A represents indole or naphthalene, and when A is indole, positions 3 and 5 of the indole are each substituted by an acetic acid group and R7O, and when A is naphthalene, positions 1 and 7 of the naphthalene are each substituted by an acetic acid group and R7O, R7 represents an alkyl group having 1 to 5 carbon atoms or a benzyl group, wherein the benzene ring of the benzyl group is optionally substituted by one or more alkyl groups having 1 to 3 carbon atoms or alkoxyl groups having 1 to 3 carbon atoms, R3 represents any one group selected from OH, OR4, NHR4, and NR4R5, and R4 and R5 are the same or different and each represents a substituted or unsubstituted alkyl group having 1 to 4 carbon atoms], and a pharmaceutically acceptable salt thereof when R3 is OH.